• Experimental rat model of type-1 diabetes was induced by streptozotocin.
Introduction
Diabetic neuropathy is one of the most common complications of diabetes affecting about 50% of patients [1] . In addition, one out of five patients with diabetic neuropathy will develop painful diabetic neuropathy (PDN), a chronic and progressive disorder described as tingling, burning, electrical or stabbing pain and hyperesthesia [2] . Importantly PDN greatly impacts the patient's quality of life causing sleep disturbances, mood and physical impairments [3] . As in other chronic diseases, some studies suggest diabetes and depression share a bidirectional relation [4] as diabetic patients are more likely to develop depression while depressive patients are more disposed to develop diabetes throughout their lifetime [5] . However, PDN management therapies are mainly aimed at preventing/retarding nerve fibre loss and alleviating painful symptoms in order to restore normal physical and psychological function [6] . The currently used PDN management therapies require prolonged administration to achieve therapeutic effect and importantly, their effectiveness is far from satisfactory [7] .
In PDN, several conditions contribute to aberrant nociceptive processing. Among them are impairment of axon-glia relationship, segmental or paranodal demyelination [8] , axonal injury [9] and regeneration [10] . In the central nervous system, the development of chronic pain in diabetes was attributed predominantly to neuronal dysfunction such as aberrant hyperexcitability of nociceptive spinal dorsal horn neurons and loss of function of inhibitory interneurons [11] . Recent works, however, showed that spinal glial cells, in particular microglia, are strongly activated and proliferate after diabetes as well as nerve injury [12, 13] . Microglia is considered essential for surveillance, protection and restoration of the CNS [14] . Additionally, after induction of diabetes an intense microglial activation was detected in the spinal cord [15, 16] and, with the progression of diabetes, evident signs of microglial activation were also present at supra-spinal level, namely in the rostroventromedial medulla (RVM), a major supraspinal modulatory centre [17, 18] . This area displayed an increase in the expression of IBA-1, a marker of microglial cells, along with morphologic alterations typical of microglial activation such as retraction of glial branches [19] . Microglia activation results in the synthesis and local release of the proinflammatory cytokines IL-1␤, IL-6, and TNF-␣ [20] that elicit robust heat hyperalgesia and mechanical allodynia [21] . Furthermore, recent studies yielded compelling evidence that releasing of proinflammatory mediators after microglial activation also play a critical role in the development of a depressive condition [22, 23] .
Interestingly, administration of minocycline, an FDA-approved second-generation semisynthetic derivate of tetracycline [24, 25] , selectively inhibited microglia activation to the classical proinflammatory state (M1), but not the activation to the alternative anti-inflammatory state (M2), which is believed to promote neuroprotection and regeneration after injury [26] . As a result, minocycline treatment attenuated hypersensitivity in several models of neuropathic pain (e.g., [27] [28] [29] ), including PDN [15, [30] [31] [32] . Moreover, minocycline has also been proposed to exert an antidepressant effect in both humans and experimental animals [22] as a result of its neuroprotective actions including increased neurogenesis [33, 34] , antioxidant activity [35] , anti-glutamate excitotoxicity [36] [37] [38] , and regulation of pro-inflammatory molecules [39, 40] .
Of the several animal models of diabetic neuropathy available, the streptozotocin-induced type-1 diabetes model was shown, in addition to robust hyperglycemia and hypoinsulinemia, to display chronic pain characterized by heat allodynia and mechanical hyperalgesia [41, 42] . This was associated from three weeks onwards with an increased number of spinal microglia [43] and depressive-like behaviour [44] . A recent study suggested that acute minocycline treatment might ameliorate depression-like behaviour in diabetic animals [45] . However, this study did not assess whether the minocycline-induced acute antidepressant-like effect was associated with attenuation of pain hypersensitivity. Since diabetes in the clinic is a chronic disease, it would be of potential clinical interest to assess whether prolonged treatment with minocycline in animals with painful diabetic neuropathy has an effective antidepressant effect as did the acute treatment, and whether the antidepressant effect is associated with suppression of pain behaviour. Therefore, we determined the effect of a three-week per os treatment with minocycline on pain sensitivity and depression-like behaviour in established PDN.
Materials and methods

Animals and ethical considerations
The experiments were performed using 24 eight week old male Wistar Han rats weighting between 250 and 325 g (Charles Rivers, Barcelona, Spain). Animals were randomly assigned two by two to boxes with soft bedding upon arrival; a blue line was painted in the tail of one rat and a red line in the tail of the other. Each box was numbered from 1 to 12, no indication concerning if the animals were assigned to the SHAM or DIAB group was displayed. The list discriminating the boxes corresponding to the SHAM or DIAB groups was kept by an independent party.
Food and water were available ad libitum and animals were maintained in a climate-controlled room, under 22 • C of temperature, 55% of humidity and a 12 h light/dark cycle with lights on at 8:00 a.m. Before the beginning of the experiments, all animals were handled daily by the experimenter for a week, and the protocols were conducted during the light phase of the cycle.
The experimental protocol followed the European Community Council Directives 2010/63/EU concerning the use of animals for scientific purposes. Moreover, all experiments were performed in accordance with the ethical guidelines for the study of pain in conscious animals [46] and were approved by the Institutional Ethical Commission (SECVS 109/2016). All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data.
As diabetes is a very debilitating disorder, several humane endpoints were established prior to the beginning of the experiment including loss of 20% weight per week, blindness, inability to move and urinary tract infections, which was supervised by the experimenters and the resident veterinary.
After the completion of the study, animals were euthanized with a lethal dose of pentobarbitone.
Induction of experimental type-1 diabetes
The induction of experimental type-1 diabetes mellitus was performed following an overnight fasting period and four weeks before the start of the pharmacological treatment, as described in detail elsewhere [47] . Briefly, animals received a single intraperitoneal injection of streptozotocin (STZ) (60 mg/kg body weight; Sigma-Aldrich, St. Louis, USA) dissolved in citrate buffer (0.1 M, pH 4.5) (DIAB) as described elsewhere [47, 48] . Control animals were injected with citrate buffer (SHAM) alone.
In each animal, development of experimental diabetes was verified 72 h later by a third party without any specific order and without prior knowledge of the box number. Glucose concentration was measured using Accu Chek Sensor Comfort (Roche Diagnostics, Germany) in blood samples collected from the tail vein.
Only those rats that displayed glucose levels higher than 270 mg/dl were included in the DIAB group. Glycaemia levels were also determined in SHAM animals. Besides hyperglycaemia, STZ-treated animals can also display major clinical signs of diabetes, such as polyuria, polydipsia and polyphagia, as well as cataract [41, 42] .
Behavioural assessment of nociception
All behavioural tests were performed during the day time, starting at 9:30 a.m. and ending at 1:30 p.m. after which the animals were returned to the animal house. All experiments were performed by trained observers and all efforts were made to ensure that the experimenters were blind to the treatment.
Tactile allodynia
Mechanical allodynia was measured using the up-down method with von Frey filaments [49] . Briefly, in an elevated grid the animals were placed inside an inverted transparent plastic box, to limit their movements, and each hind paw (ipsi-and contralateral) was probed with von Frey filaments (0.4, 0.6, 1.0, 2.0, 4.0, 6.0, 8.0, and 15.0 g; Stoelting, Wood Dale, IL, USA) on its plantar surface for 1-2 s. Testing was initiated with the application of the 2.0 filament, if no response was observed (nocifensive hind paw flexion reflex) a stronger stimulus was presented otherwise the next weaker stimulus was applied. The up-down process was repeated 4 times after the first change in response, and the 50% threshold for paw withdrawal was determined combining the individual response pattern and the value of the last von Frey filament used [49, 50] .
Cold allodynia
Cold hypersensitivity was assessed by applying a drop of acetone to the plantar surface of both hind limbs with the animals atop the elevated grid and confined by an inverted transparent plastic box. The pain-related behaviour evoked by the cooling of acetone was graded to the following 4-point scale: 0 − no response; 1 -quick withdrawal, flick or stamp of the paw; 2 -prolonged withdrawal or repeated flicking of the paw; 3 -repeated flicking and licking of the paw [51] . Acetone was applied three times to the hind paw (with 3 min interval between each successive application) and the responses scored categorically. For each animal, the average of the scores obtained in the 3 measurements was used for the analysis.
Mechanical hyperalgesia
Behavioural evaluation of mechanical hyperalgesia was performed using the paw pressure test (Randall-Selitto test, Model 37215, Ugo-Basile, Comerio, Italy) [47, 52] . To perform the test each animal was carefully immobilized in the experimenter hand and increasing mechanical forces were applied to the medial portion of the dorsal surface of both hind paws (alternately) with a cone-shaped plunger. The mechanical force (in grams) that evoked hind paw withdrawal was recorded. The paw withdrawal threshold (PWT) of each animal was considered to be the average of three consecutive measurements, sampled with 5 min intervals.
Heat hyperalgesia
Heat hyperalgesia was evaluated using the tail-flick test [53, 54] . For assessing heat hyperalgesia, a radiant heat source was placed midway in the tail of the awake animals and the time spent between the heat application and the withdrawal response (Plantar Test Instrument, Model 37360, Ugo Basile, Varese, Italy) was registered as the tail withdrawal latency (TWL). In each time point, the TWL was evaluated twice at an interval of 1 min and the mean of these values was used in further calculations. Cut-off time was 15 s.
Assessment of depressive-like behaviour
Learned helplessness using the forced-swimming test (FST) [55] , (with minor modifications) was used as an index of depressive-like behaviour. Animals were submitted to a pre-habituation session (10 min) in which they were individually placed in a cylinder filled with water (25 • C; depth 30 cm). Twenty-four hours later animals were again placed in the cylinders for a period of 5 min and the testing session was recorded with a video camera. The quantification of (i) latency to immobility, time until the first bout of immobility after placing the animal in the cylinder [56] , (ii) Immobility duration, when the animal was floating or making only minimal movements to keep the head above water; (iii) swimming duration, when the animal was making active swimming with movement of all four limbs with body aligned horizontally, and; (iv) climbing duration, when the animal was making active movements with its forepaws in and out of the water, usually directed against the cylinder walls [57, 58] . Behavioural evaluations were performed by a blind observer that rated the videos using the Etholog software [59] . Learned helplessness behaviour was defined as an increase in time of immobility at the expense of the time spent swimming/climbing and a decrease in the latency to immobility.
Drugs
Minocycline (Minotrex, Medinfar, Portugal) was prepared in sterilized tap water, and administered once a day (80 mg/kg body weight p.o.). Control treatment was performed with sterilized tap water alone (VEH; p.o.). The route of administration and concentration were chosen based on previous work indicating microglial inhibition after chronic minocycline administration [29, 30] .
Experimental design
On the week preceding the STZ injection, animals were submitted to a baseline evaluation of the general health parameters, such as body weight, blood glucose levels, and water and food intake, as well as nociceptive behaviour using the von Frey, acetone, RandallSelitto and tail-flick tests. Animals were then randomly assigned to the experimental group DIAB or SHAM, and four weeks after STZ administration all animals were again tested for nociceptive behaviour. Diabetic rats were randomly selected to receive daily minocycline (DIAB MINO) or vehicle (DIAB VEH) treatment for 3 weeks, whereas the SHAM non-diabetic rats received vehicle (tap water) alone (SHAM VEH). At the end of the pharmacological treatment all animals were again tested to assess the nociceptive and comorbid depressive-like behaviour (FST) (Fig. 1). 
Statistical analyses
To evaluate the effect of minocycline upon nociceptive and emotional-like behaviour, the minimum number of animals needed was determined à priori using the G power software (version 3.1.9.2, University of Kiel, Germany). Considering a two-way ANOVA test, an error probability of 0.05, power of 0.95 and an effect size of 0.25, the minimum number was n = 24.
The GraphPad Prism ® 6 software (GraphPad Software Inc, La Jolla, CA, USA) was used to perform the statistical analyses. Differences in weight gain, glycaemia levels, water and food consumption and nociceptive behaviours between DIAB and SHAM groups were evaluated by applying a mixed-design two-way analysis of variance (ANOVA) followed by t-test with a Bonferroni correction for multiple comparisons. The comparisons of differences between groups in the behavioural assessment were performed using a two-way and one-way ANOVA followed by t-test with a Bonferroni correction for multiple comparisons. The association between mechanical sensitivity in the von Frey test and depressive-like behaviour (immobility time and time spent swimming) was performed using a Pearson's correlation in order to explore if the suppression of Fig. 1 . Experimental design. On the week preceding the STZ injection, animals were submitted to a baseline evaluation of the general health parameters, such as body weight, blood glucose levels, and water and food intake, as well as nociceptive behaviour using the von Frey, acetone, Randall-Selitto and tail-flick tests. Animals were then randomly assigned to the experimental group DIAB (animals receiving STZ in citrate buffer, i.p) or SHAM (control animals receiving citrate buffer alone, i.p), and four weeks after STZ administration all animals were again tested for nociceptive behaviour. DIAB rats were randomly selected to receive daily per os (p.o.) minocycline (DIAB MINO) or vehicle (tap water) (DIAB VEH) treatment for three weeks, whereas the SHAM non-diabetic rats received vehicle alone (SHAM VEH). At the end of the pharmacological treatment all animals were again tested to assess the nociceptive behaviour as well as tested for the development of comorbid depressive-like behaviour in the forced swimming test. Open circles represent the repeated evaluation of general health parameters and nociception.
pain behaviour by prolonged minocycline treatment is associated with antidepressive-like effect. Statistical significance was accepted for P < 0.05. Data in the results section are expressed as mean ± standard error of the mean (SEM). All statistical analyses were performed on raw data. No method of data normalization was used.
Results
Development of metabolic signs of diabetes
Blood glucose levels, body weight, water and food intakes were measured throughout the experimental period. All STZ-injected animals exhibited hyperglycaemia (458.16 ± 68.16 mg/dl) when measured 3 days post injection. Across the experimental period, the levels of glucose in the blood varied throughout time (main effect of time: F (2,42) = 610.20, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 184.30, P < 0.001). Post-hoc tests showed higher glucose levels in DIAB VEH and DIAB MINO than in SHAM VEH animals while treatment with minocycline partly decreased the glucose levels when compared to DIAB VEH animals ( Fig. 2A) .
Body weight also varied throughout time (main effect of time: F (2,42) = 31.63, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 57.54, P < 0.001). Post-hoc tests showed decreased body weight in DIAB animal, independently of minocycline treatment, when compared with SHAM VEH animals (Fig. 2B) .
Water and food intakes were significantly altered during time (Water: main effect of time: F (2,18) = 443.20, P < 0.001); (Food: main effect of time: F (2,18) = 91.17, P < 0.001) and varied with the experimental group (Water: interaction time x group: F (2,18) = 111.00, P < 0.001); (Food: main effect of time x group: F (2,18) = 19.14, P < 0.001). Post-hoc tests showed that DIAB animals drank and ate significantly more than SHAM animals, independent of minocycline treatment (Fig. 2C,D) .
Minocycline and nociceptive behaviour in diabetic animals
Mechanical allodynia varied throughout time (main effect of time: F (2,42) = 31.63, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 19.23, P < 0.001). Post-hoc tests indicated DIAB animals gradually increase their mechanical allodynia post STZ injection with minocycline treatment partly reversing the increase of allodynia (Fig. 3A) .
Cold allodynia varied throughout time (main effect of time: F (2,42) = 10.46, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 2.63, P = 0.048). Post-hoc tests showed DIAB animals displayed increased cold sensitivity when compared to SHAM animals, an effect that was not reversed by treatment with minocycline (Fig. 3B) .
Mechanical hyperalgesia varied throughout the experimental period (main effect of time: F (2,42) = 38.46, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 16.57, P < 0.001). Post-hoc tests showed DIAB animals displayed decreased paw withdrawal threshold. Diabetes-induced mechanical hyperalgesia was not significantly influenced by treatment with minocycline (Fig. 3C) .
Heat sensitivity varied throughout time (main effect of time: F (2,42) = 29.47, P < 0.001) and with the experimental group (interaction time x group: F (2,42) = 7.02, P < 0.001). Post-hoc tests showed a decrease in heat sensitivity (increase tail-flick latency) in DIAB animals, independent of treatment with minocycline (Fig. 3D ).
Minocycline and mood-like behaviour in diabetic animals
In the FST, DIAB animals displayed depressive-like behaviour as shown by an increased immobility time (F (2,21) = 16.65, P < 0.001) (Fig. 4B) as well as decreased time spent swimming (F (2,21) = 16.39, P < 0.001) (Fig. 4C ) and climbing (F (2,21) = 4.21, P = 0.029) (Fig. 4D) , while the latency to immobility was not significantly influenced by diabetes (F (2,21) = 1.86, P = 0.180) (Fig. 4A) . The treatment of DIAB animals with minocycline improved the depressive-like phenotype by decreasing the immobility time and increasing the time spent swimming (Fig. 4B,C) , but failed to influence latency to immobility (Fig. 4A) or climbing time (Fig. 4D) . Moreover, the time animals spent immobile correlates with the mechanical sensitivity in the von Frey test (r = −0.713, n = 24, P < 0.001) as did the time spent swimming (r = −0.667, n = 24, P < 0.001).
Discussion
The present work investigated the antidepressant-like and antinociceptive effect of minocycline administration in the STZinduced type-1 diabetes experimental model. Four weeks after the induction of diabetes, animals displayed sustained hyperglycaemia, polyuria, polydipsia, polyphagia, weight gain impairment, tactile and cold allodynia, mechanical hyperalgesia and heat hypoalgesia. These findings mimic some of the features observed in non-treated diabetic human patients. The administration of minocycline partly reversed the diabetes-induced tactile allodynia, but failed to have a significant effect on the diabetes-induced mechanical hyperalgesia or heat hypoalgesia. Moreover, minocycline treatment for three weeks rescued the diabetes-induced depressive-like phenotype by reducing immobility time and increasing swimming time. Together our results suggest that minocycline could be used as adjuvant drug in pain management therapies of patients displaying PDN and comorbid depression.
Minocycline in the control of chronic pain in experimental diabetes
The present findings on mechanically evoked pain behaviour in diabetic animals are in line with those of earlier experimental animal studies demonstrating an association between prolonged diabetes and the development of chronic pain, as suggested by mechanical allodynia and hyperalgesia [60] . Concerning heat sensitivity of diabetic animals, the results from earlier animal studies have been variable. Many studies have reported heat hyperalgesia (e.g., [41] ), while some studies have reported no marked change in heat sensitivity up to eight weeks of diabetes (e.g., [61, 62] ), or heat hypoalgesia (e.g., [63] ) as in the present study. Among potential explanations for this variability in heat sensitivity are diabetesinduced changes in the skin temperature that is a confounding factor in heat pain assessments [63] , the animal strain used, and other differences in various experimental parameters. Among these is the duration of diabetes that is likely to be an important parameter explaining variability in heat sensitivity, since peptidergic intraepidermal nerve fibres that presumably are involved in transduction of noxious heat start to express signs of damage as early as four weeks after chemical induction of diabetes [64] . Damage of nociceptive nerve fibre endings may contribute to the development of heat hypoalgesia. In human studies, the development of hyper-or hypoalgesia has been inconsistent [65, 66] . It may be argued that the insensate symptoms experienced by many diabetic patients resemble heat hypoalgesia observed in diabetic animals of the present study.
Although there is a large body of pharmacological agents used in the management of diabetic neuropathy, current therapies are still unsatisfactory and the need to find new and efficient drugs remains. In the last decade, some promising data from animal models suggested that minocycline, a semi-synthetic second-generation tetracycline antibiotic able to cross the blood brain barrier, could be used to ameliorate several complications associated to diabetes, such as diabetic macular oedema [67] and neuronal death due to hypoglycaemia [68] . This drug, unlike other tetracyclines, has an absorption rate of 95-100% when orally administered. Moreover, high hydrophilic properties facilitates the crossing of the blood brain barrier, with cerebrospinal fluid presenting around 50% of the concentration found in the plasma [69, 70] . Importantly, plasma concentration is almost not affected by renal impairments, a condition usually present in diabetes [69, 70] . Further support was provided by a human study reporting that a six-week oral treatment with minocycline was safe and it improved peripheral and autonomic neuropathy in type-2 diabetic patients [71] .
Overall, minocycline was partly able to reverse nociceptive impairments induced by four weeks of experimental type-1 diabetes, as only diabetes-induced mechanical allodynia unlike mechanical hyperalgesia, cold allodynia or heat hypoalgesia was attenuated by minocycline in the present study. Earlier studies in diabetic animals reported that minocycline attenuated mechanical hyperalgesia [15] , heat hyperalgesia [30] , cold hyperalgesia or [30, 32, 72] as well as mechanical allodynia [31, 32, 72] . Among potential explanations for observing only mechanical antiallodynic effect by orally administered minocycline in the present study but no significant effect on other submodalities of pain is the route of drug administration. In line with this, drug was administered intrathecally in some of the studies reporting minocycline-induced attenuation of pain hypersensitivity to heat, cold or noxious mechanical stimulation in diabetic animals [15, 31, 72] . However, other studies also reported that systemic (intraperitoneal) administration of minocycline attenuated pain behaviour evoked by heat or cold as well as innocuous mechanical stimulation [30, 32] . Previous works on the effect of minocycline in non-diabetic neuropathic pain hypersensitivity suggested that the effect of treatment may depend on the time at which treatment started. Minocycline has been effective when treatment started early, before or within one to two days after the induction of non-diabetic neuropathic pain both with intrathecal [73] [74] [75] and systemic [27, 29, [76] [77] [78] administrations. On the other hand, when minocycline treatment started after the establishment of non-diabetic neuropathic condition, its effect on pain behaviour, independent of the route of administration, has been poor [27, 73, 78] . These earlier findings in non-diabetic neuropathic pain raise the hypothesis that starting the minocycline treatment as late as four weeks after the induction of diabetes may explain that in the present study it attenuated pain behaviour evoked by innocuous mechanical stimulation but not by other types of nociceptive testing. In line with this hypothesis, minocycline treatment that started early after diabetes induction resulted in a significant antihypersensitivity effect against various types of nociceptive stimuli in some of the studies [32, 72] . However, other earlier studies reported that minocycline treatment starting 2-4 weeks after diabetes induction effectively attenuated pain behaviour evoked by heat, cold or noxious mechanical stimulation [15, 30] .
Diabetes-induced hypersensitivity to innocuous mechanical stimulation (i.e., tactile allodynia) was significantly suppressed by minocycline in the present study. It has been reported that tactile allodynia in animals with type-1 diabetes is associated with increased activation of dorsal horn microglia as well as enhanced activation of intracellular signalling molecules associated to microglial functions [79] . This is in line with the evidence indicating that minocycline suppresses microglial activation, thereby preventing release of proinflammatory mediators [76, 80] . Another potential mechanism explaining tactile antiallodynic action of minocycline in diabetic animals is inhibition of the expression of spinal N-methyl-d-aspartic acid receptor 1 as demonstrated by Pu et al. [81] in the spinal nerve ligation model of neuropathy. It remains to be elucidated why minocycline at the dose producing a significant tactile antiallodynic effect failed to produce a significant mechanical antihyperalgesic effect in the present study. Among possible explanations is that pain behaviours evoked by innocuous versus noxious mechanical stimulation are based on at least partly different mechanisms [82, 83] and therefore, the mechanisms underlying the diabetes-induced nociceptive facilitation are differentially sensitive to minocycline. Additionally or alternatively, afferent barrage evoked by noxious stimulation is likely to be stronger than that evoked by innocuous stimulation, which may also explain why mechanical hyperalgesia is not as sensitive to suppression by minocycline treatment as mechanical allodynia.
TRPV1-expressing peptidergic nociceptive nerve fibres are considered to have an important role in transduction of noxious heat [84] . In patients with diabetic neuropathy, TRPV1-expressing cutaneous and epidermal nerve fibres were decreased [85] . In experimental animals, peptidergic intraepidermal nerve fibres were decreased four weeks after induction of diabetes [64] , at which time point we showed heat hypoalgesia and treatment period of three weeks started. These findings suggest that a loss of nociceptive nerve endings or their function may have contributed to the present decrease of heat sensitivity. In our work, treatment with minocycline failed to reverse heat hypoalgesia suggesting that minocycline may not rescue loss of heat nociceptors or their function in peripheral axon terminals of diabetic animals.
STZ-induced rat model of diabetic neuropathy [41] has also been associated with hypersensitivity to cold, which finding is in line with present results. In contrast to the present results, it has been reported that systemic minocycline treatment for two to three weeks suppressed cold hypersensitivity [30, 32] . However, this apparent controversy may reflect differences in methods used for testing cold-evoked behaviour rather than a difference in the minocycline effect. In the present study, cold hypersensitivity was assessed using a method (paw flick evoked by acetone drops on the skin) that allows assessing cold allodynia rather than cold hyperalgesia, whereas studies reporting minocycline-induced suppression of cold hypersensitivity in PDN used methods (exposure to water or plate of noxiously cold temperature) that allow assessing cold hyperalgesia rather than cold allodynia [30, 32] . Cold allodynia and cold hyperalgesia are based on at least partly different mechanisms [86] . Together these results suggest that cold hyperalgesia is more sensitive to treatment with minocycline than cold allodynia. However, in the early phase of diabetes (4th day after its induction) acute minocycline treatment had a short-lasting antiallodynic effect in cold testing as well as mechanical allodynia [72] .
It should be noted that the present study focused on a model of type-1 diabetes and therefore, the results may not be applicable to type-2 diabetes. In line with this, an earlier experimental study in animals with type-2 diabetes suggested that minocycline that inhibits microglia was inefficient in attenuating pain hypersensitivity, while a drug inhibiting astrocyte activation efficiently attenuated pain hypersensitivity induced by type-2 diabetes [87] .
Minocycline in the control of diabetes-associated emotional impairments
In the present study, diabetic animals displayed depressivelike behaviour in the FST. The association between chronic PDN and the development of emotional disorders is well established in patients [88, 89] and rats [48, 90] . In the rat, the attempt at controlling diabetes-induced depressive-like behaviour has been explored using several drugs including antidepressants such as fluoxetine [91] and imipramine [92] , antioxidants such as N-acetylcysteine [93] and endocannabinoids such as anandamide [48] among others.
A recent study in fully established STZ-induced diabetes showed that one-day intraperitoneal treatment with minocycline reversed the diabetes-induced reduction in swimming in the FST and this acute antidepressive-like effect of minocycline was associated with suppression of a neuroinflammatory pathway in the hippocampus of diabetic animals [45] . The present study is in agreement with this recent finding and extend it by showing that the antidepressive-like effect of minocycline in established diabetes is maintained even when the daily minocycline treatment is prolonged at least up to three weeks. Moreover, the antidepressive-like effect of prolonged minocycline treatment was associated with tactile antiallodynic effect in PDN. Chronic pain per se has been associated with comorbid depression-like behaviour in various experimental pain models [94] [95] [96] [97] [98] and therefore, it might be argued that the present antidepressive-like effect of minocycline was indirectly caused by attenuation of diabetes-induced pain. However, the finding that the antidepressive-like effect of minocycline was associated only with mechanical antiallodynic effect but not with corresponding changes in other submodalities of pain suggests that it may be at least in part due to action on emotion-related mechanisms [45] .
Even though a commission of experts in mental health and in diabetes stressed the need to fill the gap of knowledge concerning comorbid diabetes and depression [99] , most works evaluating the efficiency of different types of drugs in the treatment of diabetes comorbidities, both in patients and in rodents, still mostly focus on managing pain and sleep disorders, rarely anxiety and seldom even address depression [100] [101] [102] [103] [104] . By demonstrating the dual effect of minocycline upon diabetes-induced nociceptive and depressive-like impairments we highlight the potential use of this already FDA-approved drug as an alternative to the most commonly used, but still inefficient in both pain and depression, therapies such as anticonvulsants or antidepressants. Our data also provide further evidence of the importance of microglia activation in the pathophysiology of pain and depression related to diabetes. Consequently, drugs targeting microglia activation might be suitable candidates in novel pain management therapies.
The proposal that minocycline might be useful in treatment of depression is supported by the finding that minocycline suppressed depression-like symptoms also in non-diabetic conditions, such as when induced by mild foot shocks [105] . Importantly, in human subjects, minocycline treatment was able to reduce the affective dimension associated with traumatic neuropathic pain [106] further supporting the proposal that minocycline might be a treatment option in clinical conditions.
Conclusions
STZ-induced model of type-1 diabetes displayed, after four weeks, mechanical allodynia and hyperalgesia, cold allodynia and heat hypoalgesia indicating that the animals had developed a PDN-like condition. These sensory findings were associated with depression-like behaviour. A three-week per oral treatment with minocycline (80 mg/kg once a day) starting on the fourth week of diabetes significantly attenuated mechanical allodynia and depression-like behaviour, while the effect of minocycline on other sensory responses was not significant. The results support the hypothesis that prolonged per oral minocycline treatment may provide a treatment option against mechanical hypersensitivity and comorbid emotional disorders in chronic PDN.
